Funding Agency: Alzheimer’s Drug Discovery Foundation

The Alzheimer’s Drug Discovery Foundation was established in 2004 as a public charity to support the advancement of drugs to prevent, treat, and cure Alzheimer’s disease, related dementias, and cognitive aging. Since 1998, the ADDF has granted more than $51 million to fund over 370 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 19 countries.

Call type and title: 2015 Request For Proposals

1) The ADDF/Belfer ApoE Therapeutics Innovation Program

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms.

Budget: The ADDF will provide 1 or 2 years funding for up to $300,000 per application for pre-clinical programs, and up to $1,000,000 per application for clinical trials of novel agents.

2) PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT) RFP

The goal of this Request for Proposals (RFP) is to increase the number of innovative drugs tested in humans for Alzheimer’s disease, related dementias and cognitive aging. This program will fund biomarker-based pilot clinical trials for Alzheimer’s disease and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. The ADDF is also interested in supporting targeted pharmacological and non-pharmacological approaches to prevention.

Programs areas of particular interest include:
Repurposing – Testing drugs approved for other indications in Alzheimer’s disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.
Therapies addressing the following targets: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.

Budget: up to $1,500,000 per application. Multi-year proposals will be considered.

3) PRECLINICAL DRUG DISCOVERY RFP

The Alzheimer’s Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer’s disease, other dementias and cognitive aging.

PRECLINICAL RESEARCH FUNDING PRIORITIES:
Drug Discovery - Target validation, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization-, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics.
Biomarker Development - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.

Budget: Funding averages $150,000 per year and must be justified based on the scientific work plan. In some cases, multi-year proposals can be considered.
<table>
<thead>
<tr>
<th><strong>Submit to the Research Authority till</strong></th>
<th><strong>LOI</strong>: 17/5/15, 20/8/15, 10/11/15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For More Information</strong></td>
<td>The ADDF/Belfer ApoE Therapeutics Innovation Program</td>
</tr>
<tr>
<td></td>
<td>PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT)</td>
</tr>
<tr>
<td></td>
<td>PRECLINICAL DRUG DISCOVERY</td>
</tr>
<tr>
<td><strong>Forms</strong></td>
<td><strong>On-line application</strong></td>
</tr>
<tr>
<td><strong>How to submit</strong></td>
<td>Applications must be submitted to Research Authority by email: <a href="mailto:michalsh@ariel.ac.il">michalsh@ariel.ac.il</a>. Additional, you requested to send me this &quot;Proposal Form&quot; with signature of head of department before submission.</td>
</tr>
<tr>
<td><strong>Funding Agency Homepage</strong></td>
<td><a href="http://www.alzdiscovery.org/">http://www.alzdiscovery.org/</a></td>
</tr>
</tbody>
</table>

ל探究 כל כך לשאר היזמותו הפמיניות הפרוגנוזות עדין להנשא

*Before printing this Call for proposal think about your commitment to the Environment.*